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Abstract
Background: The genetic contribution to sporadic amyotrophic lateral sclerosis (ALS) has not been fully elucidated. There
are increasing efforts to characterise the role of copy number variants (CNVs) in human diseases; two previous studies
concluded that CNVs may influence risk of sporadic ALS, with multiple rare CNVs more important than common CNVs. A
little-explored issue surrounding genome-wide CNV association studies is that of post-calling filtering and merging of raw
CNV calls. We undertook simulations to define filter thresholds and considered optimal ways of merging overlapping CNV
calls for association testing, taking into consideration possibly overlapping or nested, but distinct, CNVs and boundary
estimation uncertainty.
Methodology and Principal Findings: In this study we screened Illumina 300K SNP genotyping data from 730 ALS cases
and 789 controls for copy number variation. Following quality control filters using thresholds defined by simulation, a total
of 11321 CNV calls were made across 575 cases and 621 controls. Using region-based and gene-based association analyses,
we identified several loci showing nominally significant association. However, the choice of criteria for combining calls for
association testing has an impact on the ranking of the results by their significance. Several loci which were previously
reported as being associated with ALS were identified here. However, of another 15 genes previously reported as exhibiting
ALS-specific copy number variation, only four exhibited copy number variation in this study. Potentially interesting novel
loci, including EEF1D, a translation elongation factor involved in the delivery of aminoacyl tRNAs to the ribosome (a process
which has previously been implicated in genetic studies of spinal muscular atrophy) were identified but must be treated
with caution due to concerns surrounding genomic location and platform suitability.
Conclusions and Significance: Interpretation of CNV association findings must take into account the effects of filtering and
combining CNV calls when based on early genome-wide genotyping platforms and modest study sizes.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease of motor neurons resulting in progressive weakness and
death, usually within about 3 to 5 years of diagnosis as a result of
neuromuscular respiratory failure. The lifetime risk of ALS is
about 1 in 400[1] with peak incidence in the sixth decade but the
causes remain largely unknown. In about 10% of cases there is a
family history. Following linkage, mutations causing familial ALS
have been identified in the genes SOD1 [2–4], TARDBP[5,6], and
FUS(TLS)[7] accounting for about 20 to 30% of cases, and ALS2
[8–10], SETX[11–13], and VAPB[14] accounting for some
atypical, rare forms.
Attempts to identify genetic causes for the common sporadic
form of ALS have met with limited success. Candidate gene
analyses have identified NEFH deletions and insertions[15–17],
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8175and ANG mutations[18–22] as possible risk factors, and both have
also been identified in affected individuals from families with ALS.
Genome-wide association studies have not found a single
consistent risk variant but ITPR2[23], DPP6[24] and
UNC13A[25] variants have been identified in some studies, and
KIFAP3 identified as a survival gene[26]. The numbers studied are
still in the low thousands and research is therefore continuing.
Copy number variation of the SMN gene, responsible for spinal
muscular atrophy, has been implicated as a risk factor for sporadic
ALS[27]. Two previous studies have examined copy number
information derived from genome-wide association studies of
ALS[28,29] concluding that multiple rare copy number variants
(CNVs) may be a more important risk factor for sporadic ALS
than common CNVs. A study utilising data from a combined total
of 651 ALS cases and 625 controls, genotyped on either the
Illumina 300K or the Illumina 550K SNP chip, identified 39 loci
that were highlighted as containing rare ALS-specific copy
number changes[28]: plausible candidate regions within this
category included an ataxin gene locus and the hereditary
haemochromatosis locus. In the same study and a previous study
based on a subset of the same data (406 ALS cases and 404
controls)[29], nominally significant associations between CNVs
that were not ALS-specific and risk of ALS were found for a total
of 25 loci. However, none of these associations remained after
Bonferroni correction for multiple testing.
Sophisticated algorithms are available to mine SNP genotyping
data for CNVs[30–32]. However, many SNPs in CNV regions
have been excluded from some genome-wide genotyping plat-
forms due to the effect of copy number variation on Hardy-
Weinberg equilibrium and Mendelian inheritance[33]. Boundary
uncertainty due to low resolution of the platform can lead to CNV
calls that arise from underlying neighbouring or nested, but
distinct, CNV events being clustered together across individuals as
representing the same CNV[33]. The challenge lies in accurately
combining calls that may not be identical across individuals but
which arise as the result of the same underlying signal and
distinguishing calls that overlap because of boundary uncertainty.
In addition, it is known from the study of genomic disorders that
overlapping or nested CNVs can give rise to distinct phenotypic
characteristics [34–36]. Therefore, an approach which combines
any overlapping CNV calls could lead to misclassification of CNV
regions. In addition to sample size and genome coverage, the
misclassification of CNV regions could explain the thus far weak
associations with CNVs found for ALS.
In this study, CNV calls derived from Illumina HumanHap 300
v.1.0 SNP array intensity data from an initial sample size of 730
ALS cases and 789 controls were analysed for association with
ALS. CNV calls were merged into distinct, nested and overlapping
CNV regions for association analysis. A gene-based association
approach was also used for comparison and to test the hypothesis
that multiple, rare CNVs affecting a subset of genes and pathways
may contribute to ALS risk. We compared our findings with those
of previous studies.
Results
Genome-Wide CNV Detection: Raw CNV Calls
Following the sample quality control filters, 621 cases and 675
controls remained for further analysis (age and sex details of the
cases and controls are given in Table 1). A total of 80023 unfiltered
CNV calls were made from the data. These calls were filtered
according to log Bayes factor (posterior measure of confidence in
the call) and proximity to the centromere and CNV calls from
individual samples with an extreme number of CNV calls across
their genome were also excluded (see Methods). To facilitate
comparison with published findings we did not exclude calls within
the telomeric band (but loci containing these calls are flagged
where appropriate in subsequent sections of the results). Following
these filters, a total of 11321 CNV calls across 1194 samples (14 of
which contained no CNVs after filtering) remained. The total
number, mean numbers per individual and median sizes of each
type of CNV are given in Table 2. A two-tailed Mann Whitney U-
test was used to compare the mean number of CNVs per
individual and the median size of the CNVs of each type between
cases and controls. ALS cases were found to contain significantly
more duplications (p=0.0018) and significantly larger duplications
(p,0.001) than controls.
Genome-Wide CNV Association: By CNV Region
CNV calls that passed the filters described above from across all
individuals were merged into CNV loci for association testing (see
Methods). This region-based approach enables consideration of
boundary estimation uncertainty and the possibility of distinct but
nested or overlapping CNV loci. A reciprocal overlap threshold of
.70% was used initially and a total of 2983 CNV loci (median size
72.9 kb) across the genome were identified. Of these, 119 (median
size 90.6 kb) were observed to be ALS-specific (i.e. present in 2 or
more ALS cases but not observed in any controls) and 136 (median
size 79.1 kb) were observed to be control-specific (i.e. in 2 or more
control samples but not observed in any cases) (Table 3). There
was no significant difference between the number of ALS-specific
CNV loci and the number of control-specific CNV loci either
overall or by CNV type (heterozygous deletions, homozygous
deletions, duplications, multiallelic [loci consisting of both
duplications and deletions]). Five loci were found to contain both
heterozygous and homozygous deletion calls – all five of these
CNV regions were identified only in controls and none were found
in cases (p=0.03). There was no significant difference between the
size distribution of ALS-specific or control specific heterozygous
deletions, homozygous deletions or duplications. The control-
specific multiallelic loci were found to be significantly larger
(p=0.028) than the ALS-specific multiallelic loci (median sizes of
Table 1. Sex and age of sample population following sample quality control.
Case Control Overall
n Mean age Age range n Mean age Age range n Mean age Age range
Male 392 52.0 21–86.5 389 62.4 25–95 781 57.2 21–95
Female 229 56.9 19–83 286 54.9 21–89 515 55.8 19–89
Total 621 53.8 19–86.5 675 59.2 21–95 1296 56.6 19–95
doi:10.1371/journal.pone.0008175.t001
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loci were observed in more than 1% of samples and 24 were
identified in more than 5% of samples.
Of the 2839 autosomal loci (defined from CNV calls using a
reciprocal overlap threshold of .70%) tested for association with
ALS, 31 showing gains in copy number were associated with ALS
(uncorrected nominal p,0.05, Table 4 and Table S1 and Table
S2). Loci within the telomeric band are flagged and the proximity
of each loci to the centromeres is indicated in Table 4. Only the
top locus on chromosome 5 was associated after Bonferroni
correction for multiple testing. Of these, 26 were found at a
frequency of greater than 1% in the study population with 9 of
these having a frequency of greater than 5% (although all but one,
the RDH13 region, map very close to the centromere: a region
believed to be prone to false positive CNV calls). Eleven of the
thirty-three ‘‘gains’’ loci overlapped at least one Copy Number
Polymorphism (CNP), identified by McCarroll and colleagues[37]
as copy number loci with a frequency of .1% in the HapMap
population. Four CNV loci showing loss of copy number were
associated with ALS (nominal p,0.05). Only one of these ‘‘loss’’
loci was present at a frequency of greater than 1% and this locus
also overlapped a CNP. Finally, two further loci showing both
losses and gains in copy number across the study population were
associated with ALS. One of these two loci was present at a
frequency of greater than 1% in the study population and also
overlapped a CNP.
Sensitivity Analyses
For each of the loci defined using a 70% reciprocal overlap that
reached p,0.05, the raw CNV calls within these regions were re-
assigned to CNV loci using different reciprocal overlaps (.0%,
.50% or 100%). Where re-assignment resulted in more than one
CNV locus within the region defined using 70% overlap, the locus
giving the highest significance was included(Table 5). The choice
of reciprocal overlap threshold used has an effect on the order of
significance of the loci with some loci reaching smaller p values if
different thresholds are used while others give a higher p value or
are lost as nominally significant loci. Although the ‘‘top’’ locus on
chromosome 5 retained a very low p value for all thresholds, the
second and third ranking loci gave p values of .0.01 if any overlap
(.0%) or a .50% threshold was used. Three loci that achieved a
p value,0.05 when a 70% reciprocal overlap was used were lost if
any of the other overlap thresholds were used to combine the raw
calls.
Genome-Wide CNV Association: By Gene
In addition to the region-based approach described above, a
gene-based association analysis was also undertaken to accommo-
date the hypothesis that multiple rare CNVs may contribute to
ALS risk by affecting one or a subset of key genes. The numbers of
CNV calls that overlap each gene (at least 1 base pair overlap)
were counted and the difference between the number called in
cases and the number called in controls per gene was tested.
Table 2. Overall summary of CNV calls across 1194 (575 cases and 619 controls) individuals.
Type Cases Controls P value
Duplications Total 4015 3941
Mean per individual (range) 7.03 (0–21) 6.44 (0–21) 0.0018
Median size, kb (range) 202.3 (0–3074) 160.3 (0–10000) ,0.0001
Heterozygous deletions Total 1416 1685
Mean per individual (range) 1.13 (0–6) 1.12 (0–2) 0.4115
Median size, kb (range) 47.6(0.57–1513) 46.8 (0.35–9888) 0.1127
Homozygous deletions Total 128 136
Mean per individual (range) 2.77 (0–14) 2.99 (0–16) 0.2247
Median size, kb (range) 5.38(0–425) 5.5(0–383) 0.8699
Total 5559 5762
Significant p values are given in bold.
doi:10.1371/journal.pone.0008175.t002
Table 3. ALS-specific and control-specific CNV counts.
Type ALS-specific (n) Control-specific (n) P value*
ALS-specific: median
size (kb)
Control-specific: median
size (kb) P value{
All 119 136 0.69 90.6 79.1 0.52
Heterozygous deletions 50 50 0.68 53.9 49.8 0.48
Homozygous deletions 5 4 0.65 2.4 23.4 0.62
Duplications 59 68 0.74 158.7 103.0 0.14
Multiallelic 5 9 0.36 49.5 395.1 0.028
Deletion (het or hom) 0 5 0.032 na 8.3 na
ALS-specific CNVs defined as those present in 2 or more ALS cases but in no controls. Control-specific defined as those present in 2 or more controls but no ALS cases.
*Pearson’s chi-squared test, 1 df.
{Mann-Whitney U-test.
doi:10.1371/journal.pone.0008175.t003
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with ALS using the gene-based approach were also identified using
the region-based approach (Table 6). Twenty-eight of these genes
were significantly associated with ALS using a gene-based
approach at a significance level of p,0.01. The 8 most significant
genes were all located within the chromosome 11 region (build 36
coordinates – chr11:539119-652407) which showed ALS-specific
loss in copy number in 5 samples (this region was also found to
show significant association with ALS if different reciprocal
overlap thresholds were used to merge the data into CNV regions,
but with gains in copy number showing association). Figure 1
shows the raw CNV calls and how these are clustered into CNV
regions at this locus.
Gene Set and GRAIL Analysis
Gene Set Analysis (GSA) and GRAIL analyses were carried out
on the CNV regions and ALS-specific/control-specific CNV calls,
respectively, to identify any gene-sets that might contain ALS-
associated copy number variation. For GSA, no gene-set was
associated with ALS using a significance threshold of
p,5.74610
24 (Bonferroni corrected). Table S3 shows all
pathways with p,0.05. Four of these nominally significant
pathways are involved in apoptosis and cell death, one in muscle
organ development (identified using both region-based and gene-
based p-values) and one in central nervous system development.
No significantly associated genes were identified from the ALS-
specific CNV calls using GRAIL but five genes significantly
associated with the control-specific CNV calls were identified
(Table S4).
Candidate Regions/Previously Detected Regions
Regions that were previously identified to show association with
ALS were investigated in our data. ALS-specific gains and losses
were observed in 6 ALS cases at the GSDMD gene region
(association p value=0.012). This region was also previously
identified by Cronin and colleagues[28] as containing ALS-specific
gains and losses. GSDMD was also found to be significantly
associated (p,0.01) with ALS in our gene-based approach. Of the
other 15 genes identified to exhibit ALS –specific copy number
variation by Cronin and colleagues[28] only four were also found
to exhibit copy number variation in this study but in both cases
and controls and with no significant differences between them
using either approach.
A region 473.4 kb downstream of SH2D4B region on
chromosome 10 showed association with ALS by loss of copy
number in this study, using a region-based approach, with 7 ALS
cases and 22 controls containing a loss at this locus. A significant
association with ALS with losses in 9 ALS cases and 21 controls at
the SH2D4B locus was reported by Cronin and colleagues[28].
Three further loci that were identified as showing significant
association with ALS in this study were also identified as
significantly associated with ALS by Cronin and colleagues[28]:
the chromosome 5 locus flanking HCN1, the chromosome 8 locus
flanking POTE8 and the chromosome 11 locus including OR4A5
and flanking OR4C12 (this locus was lost from our region-based
approach upon conversion of genome coordinates to build 36, see
table S1). However, the direction of effect was different in this
study with significant differences found between the numbers of
ALS cases and controls with gains of copy number at these loci
(losses of copy number at these loci were reported in the previous
study).
Discussion
With a sample size of 1194 (575 ALS cases and 621 controls)
and genotypes across more than 317,000 SNPs, we set out to
investigate the role of copy number variation in ALS using a
widely available CNV calling algorithm. We used two different
approaches to collate and test association of the raw CNV calls
with ALS and compared our results with those of previous studies.
Although none of the loci identified as being associated with ALS
contained, or were close to, any genes previously reported as
plausible ALS candidate genes [38,39], several potential new genes
Table 5. Sensitivity analyses.
chr start end
P value
(70%) .0% .50% 100%
Gains
5 45850032 46384240 1.07E-09 ** ** **
8 47062007 47406312 8.21E-05 - * **
12 36528296 36801139 0.000265 * * **
19 32615675 32935836 0.000587 * ** **
7 61663407 62155064 0.0018 ** ** **
3 33270957 33296620 0.0027 ** ** *
8 47062007 47711911 0.0032 - * **
8 43689385 43910848 0.0046 - * **
16 969913 1834962 0.0056 - * *
5 28842013 28912873 0.0058 * ** -
4 761587 1014752 0.0068 ** ** *
5 510955 738748 0.012 - - -
20 60320976 60493125 0.016 ** ** -
19 32615675 32851754 0.022 * ** **
6 58675121 58878583 0.024 ** ** **
19 60270514 60293927 0.025 * ** *
14 103232016 103721150 0.025 - * -
20 60214968 60493125 0.035 ** ** -
16 1744358 1781034 0.038 - * *
14 104197399 104356204 0.043 - - -
8 142512205 142529990 0.046 - - -
3 101837214 101916282 0.047 * * *
21 43646295 43663581 0.047 * * **
14 19375271 19536664 0.049 * * -
11 382079 434628 0.049 ** * *
Losses
22 21011312 21394287 0.002 * ** -
10 82869699 82882268 0.013 ** * *
11 539119 652407 0.025 ** * -
17 43969101 44059535 0.032 - * -
Losses/gains
8 47224322 47711911 0.003 - * **
8 144686338 144765210 0.012 ** ** -
For each of the loci defined using a 70% reciprocal overlap that reached
p,0.05, the raw CNV calls within the regions were re-assigned to CNV loci using
different reciprocal overlaps (.0%, .50% or 100%). Where re-assignment
resulted in more than one CNV locus within the region defined using 70%
overlap, the locus giving the highest significance was included.
**p value,0.01,
*p value,0.05, - p value.0.05.
doi:10.1371/journal.pone.0008175.t005
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encompasses several genes that are reasonable candidates for ALS
susceptibility. These have functions in calcium signalling (CAC-
NA1H), axonal transport, (MAPK8IP3), nerve growth factors
(IGFALS), angiogenesis (BAIAP3), and the ubiquitin proteasome
system (UBE2I, SPSB3). The CPLX1 gene on chromosome 4
encodes a protein involved in synaptic vesicle exocytosis. The
PPP1R13B gene on chromosome 14 is an apoptosis stimulating
protein. Perhapsthe most interesting potentialALScandidate of the
genes identified here is EEF1D, a eukaryotic translation elongation
factor 1 delta on chromosome 8, which encodes a subunit of the
elongation factor-1 complex, responsible for the enzymatic delivery
of aminoacyl tRNAs to the ribosome. This process has been directly
implicated in genetic studies of motor neuron diseases
(GARS[40,41], YARS[42] and IARS[43] genes), and the RNA
processing pathway in general is involved in amyotrophic lateral
sclerosis as evidenced by ALS-linked mutations identified in the
SETX, FUS and TARDBP genes[5–7,11–13], and the association of
ALS with variants in the ANG[18–22] and ELP3[44] genes.
Although we found few differences between the numbers and
sizes of ALS-specific and control-specific regions overall, we
identified 5 regions that were ALS-specific and achieved
significance (before multiple testing correction). Many of the genes
in these regions were also associated when the raw CNV calls were
tested using a gene-based approach, including EEF1D and
PPP1R13B. Although we found the copy number variation at a
chromosome 11 region to be ALS-specific in our sample
population, CNVs at this locus in healthy individuals have been
recorded previously [45] and are recorded in the Database of
Genomic Variants[46] suggesting that this region may not be
ALS-specific.
There wasa small amount ofoverlap between theresults fromthis
study and those of a previous study investigating the role of CNV in
ALS risk but the majority of the findings of the previous study were
not replicated in our data. Cronin et al[28] found a significant
differencebetweenthe median sizeofheterozygous deletionsincases
and controls. In this study, the median size of heterozygous deletions
was larger in cases compared to controls but this difference was not
found to be significant. When our data was filtered using an
alternative set of filters that were closer to those implemented by
Croninetal[28](seeAppendixS1),thesizeofheterozygousdeletions
were found to be larger in cases than in controls but the difference
did not reach significance (p,0.05). Significant (P,0.01) differences
between the mean number per individual and the median size of
duplications were found between cases and controls using both our
original filters and those similar to Cronin et al[28].
Our primary analysis was undertaken using a region-based
approach which aimed to reduce the impact of errors in boundary
Table 6. Results of gene-based association approach.
Gene Pooled gains and losses Losses Gains
Cases Controls P value Cases Controls P value Cases Controls P value
C11orf35 14 0 3.96E-05 8 0 0.002988 6 0 0.01271
LRRC56 14 0 3.96E-05 8 0 0.002988 6 0 0.01271
RASSF7 13 0 8.13E-05 7 0 0.006159 6 0 0.01271
MUPCDH 12 0 0.000167 6 0 0.01271 6 0 0.01271
PHRF1 12 0 0.000167 6 0 0.01271 6 0 0.01271
IRF7 12 0 0.000167 6 0 0.01271 6 0 0.01271
SCT 12 0 0.000167 6 0 0.01271 6 0 0.01271
DRD4 11 0 0.000343 6 0 0.01271 5 0 0.026252
EEF1D 10 0 0.000705 7 0 0.006159 3 0 0.112288
NAPRT1 9 0 0.00145 6 0 0.01271 3 0 0.112288
C8orf73 9 0 0.00145 6 0 0.01271 3 0 0.112288
GSDMD 9 0 0.00145 6 0 0.01271 3 0 0.112288
FBXL2 4 21 0.001771 4 21 0.001771 0 0 na
BCR 8 26 0.004875 1 4 0.375881 7 22 0.013279
C14orf2 7 0 0.006159 7 0 0.006159 0 0 na
PPP1R13B 7 0 0.006159 7 0 0.006159 0 0 na
DEAF1 7 0 0.006159 6 0 0.01271 1 0 0.482008
LAMA5 27 56 0.006206 27 56 0.006206 0 0 na
PRAME 9 27 0.006383 2 5 0.454278 7 22 0.013279
FGFRL1 19 6 0.007514 19 6 0.007514 0 0 na
IDUA 19 6 0.007514 19 6 0.007514 0 0 na
SLC26A1 19 6 0.007514 19 6 0.007514 0 0 na
GATA5 3 15 0.008199 3 15 0.008199 0 0 na
ZNF280B 9 26 0.009548 2 4 0.6881 7 22 0.013279
ZNF280A 9 26 0.009548 2 4 0.6881 7 22 0.013279
Results are ranked by p-value when gains and losses are pooled together. A 2-sided Fishers exact test was used to test for association. Genes which we considered
reasonable ALS candidates are in bold.
doi:10.1371/journal.pone.0008175.t006
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applied to the data to merge CNV calls into CNV regions and, of
the 38 loci showing association with ALS if a .70% reciprocal
overlap was used, all but 3 regions were also associated with ALS
(nominal P,0.05) if a different reciprocal overlap threshold was
used (i.e. any overlap, .50% overlap and 100% overlap).
However, the level of significance achieved varied for most
regions according to the overlap threshold used; if validation were
to be undertaken for a limited number of regions, the choice of
such regions would be dependent on the choice of reciprocal
overlap threshold used. Interestingly, many of the regions
identified using the region-based approach, were also represented
amongst the hits from the gene-based analysis. The potentially
interesting genes within the chromosome 16 region and CPLX1
were not significantly associated with ALS under the gene-based
approach. However, EEF1D and PPP1R13B were significantly
associated with ALS using both approaches.
No evidence of any gene set being overrepresented amongst
those affected by ALS-specific copy number variation was found
by GRAIL analysis. There were five significant genes amongst
those affected by control-specific copy number variation, identified
by GRAIL analysis, including GLL1 which is involved in B cell
biology and has been associated with agammaglobulinemia[47].
No significantly associated gene-sets were identified using GSA
although several involving cell death, muscle organ development
and central nervous system development were amongst those
showing nominal significance (uncorrected p,0.05). If a result that
is significant in a CNV genome-wide association study is not
significant in GSA it might still be important if it perturbs a
pathway. For example, a deletion upstream of the IRGM gene
affects the expression of IRGM but the gene itself is not believed to
be copy number variable [48]. In this case GSA using CNV
association data would not report the IRGM-related pathways.
Previous studies have found limited evidence for a role of CNV
in sporadic ALS hypothesising that multiple rare variants are more
likely to contribute to risk than common variants. In this study,
although nine copy number variable regions found in more than
5% of the study population showed association with ALS, seven of
these were found to map close to the centromeres and may be
artefactual. In addition, the regions on chromosomes 4, 8, 14 and
16 which are reported here as being associated with ALS and
containing potential ALS candidates all lie within the telomeric
chromosome band and so must also be treated with caution. The
telomeric and centromeric regions may be more prone to false
CNV calls than other regions of the genome, in part due to the
lower density coverage of older genotyping arrays in these regions.
Findings based on newer generation SNP arrays (which also
include non-SNP copy number variation probes) have shown
strong evidence of common CNVs in these regions [37] suggesting
that there may be true copy number variants in these regions
although caution must be taken when studying these regions on
older platforms. The gene-based approach also reported genes
from within some of the region-based approach findings, including
the regions on chromosomes 8 and 14 which contain potential
ALS candidate genes. The chromosome 11 region at which ALS-
specific copy number variation was observed was reported using
both approaches (with p,0.01 for each gene using gene based
approach and p=0.025 using region-based approach, although
this region also lies within 1.5 Mb of the telomere and therefore
must be treated with caution). Evidence of association in regions
for which copy number variation has previously been charac-
terised by McCarroll and colleagues [37] suggests that a role of
common copy number variation in ALS risk should not be ruled
out. It should be noted that the HumanHap300 chip has low (or
no) coverage of regions known to contain common copy number
variants and further studies involving larger sample sizes and using
denser SNP arrays or SNP-CNV hybrid arrays should be
undertaken to further investigate the role of CNV in ALS and
provide replication of the findings presented here.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Massachusetts General Hospital. All
patients provided written informed consent for the collection of
samples and subsequent analysis.
Participants
Study participants were individuals of European ancestry
attending the ALS Clinic of the Massachusetts General Hospital,
Boston, MA, USA. All cases fulfilled the El Escorial criteria for
Definite or Probable ALS. Controls were spouses or others
attending with the patient (all unrelated), or blood donors from the
same geographical region and matched for age. Patients with a
family history of ALS were excluded.
DNA was extracted from whole blood using standard methods
after written informed consent. Genotyping was performed with
Illumina BeadArrays at the Broad Institute in Boston (Human-
Hap300 v.1.0).
CNV Calling
Log R ratios and B allele frequencies for 1519 samples,
including 730 ALS cases and 789 control samples, across all
Figure 1. All CNV calls andCNV regionsoverlappingCNV region
chr11: 539119-652407. Raw CNV calls are shown in dark grey. No
control losses or gains were detected within the region shown but 8
gains in cases and 6 losses in cases were detected. Blue bars represent
CNV regions defined by merging CNV calls that share a greater than
70% reciprocal overlap. The purple bar represents the CNV region
found to show significant association in this study: the CNV calls that
were merged into this CNV region are indicated with an asterisk. Genes
are shown at the bottom. Genomic position is shown along the top.
doi:10.1371/journal.pone.0008175.g001
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software (Illumina, San Diego, CA, USA). QuantiSNP [32] was
used to screen the genotyping data for CNVs. One sample failed to
run due to at least 26,000 missing SNPs and was excluded. All
remaining samples were filtered for quality using thresholds of the
log R Ratio (LRR) and B allele frequency (BAF) outlier rates and
standard deviations recommended by the program authors[32].
Samples with LRR or BAF outlier rates of .0.05 or with log R
ratio or B allele frequency standard deviations of .0.35 or .0.1,
respectively, following GC correction were excluded (Figure 2).
Following these sample quality control filters, 621 cases and 675
controls remained. A total of 80023 unfiltered CNV calls were
made from the data.
Filtering CNV Calls
In order to minimise the number of false positive CNV calls
without compromising the sensitivity of detection of true CNVs,
we undertook simulations to define appropriate filtering thresholds
(see Appendix S1 and Figure S1). QuantiSNP provides a log Bayes
factor (LBF) value for each CNV call, which is a posterior measure
of confidence in the call. From the simulations, a log Bayes factor
threshold of 6 was chosen (figure S1). A total of 60596 calls were
found to have a log Bayes factor of less than 6 and were excluded.
Although it was found that there was very low sensitivity for
detecting small CNVs, no length filters were chosen as filtering on
length was found to decrease the sensitivity of the method to detect
longer CNVs.
Any calls that overlapped the centromeres (coordinates obtained
from the relevant version of the UCSC genome browser database)
were excluded (625 out of 19427). As a major aim of our study was
to enable independent comparison with previously published loci,
we did not exclude CNV calls which were within the telomeric
chromosome band. Samples that were outliers in terms of the
number of CNV calls across their genome were excluded along
with their calls (7481 out of 18802 calls and 102 samples). The
threshold for this was calculated using the upper quartile+1.5x(-
IQR) [28,29].
Defining CNV Regions
CNV calls were clustered into CNV loci using a reciprocal
overlap threshold (Figure 3). A threshold of .70% (pairs of CNV
calls being compared must each be over at least 70% of the other
CNV) was chosen. Thresholds of .0% (i.e. any overlap), .50%
and 100% were also tested (sensitivity anal ysis) to investigate the
effect this has on the association testing results under the rationale
that combining CNV calls must also take into account the
biological phenomenon of nested or overlapping CNVs along with
the uncertainty of boundary estimation by the method used.
Figure 2. Sample quality measures (log R ratio and B allele frequency outlier rates and standard deviations). Maximum LRR standard
deviation against maximum BAF standard deviation (top) and maximum LRR outlier rate against maximum BAF outlier rate (bottom). Thresholds for
exclusion are shown in red.
doi:10.1371/journal.pone.0008175.g002
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largest CNV call was assigned the initial CNV locus identifier.
Each subsequent CNV call was then compared to all CNV calls
previously assigned to a CNV locus and was in turn allocated to
the CNV locus for which it showed a reciprocal overlap of greater
than the chosen threshold with all CNV calls already allocated to
that locus. If it did not meet the overlap criteria for all CNV calls
currently assigned to any of the previously designated CNV loci, it
was assigned to a new CNV locus. This allows nested CNV loci to
be designated and prevents CNV loci from ‘‘spreading’’ such that
they contain CNV calls that do not overlap one another.
Defining Gene Overlap for Gene-Based Association
The coordinates of all 11321 CNV calls that passed the filters
above were mapped from Build 35 to Build 36 of the human
genome (Batch Coordinate Conversion tool, UCSC Genome
Bioinformatics Group) in order to extract the number of calls that
overlapped each gene (Table Browser tool, UCSC Genome
Bioinformatics group). A total of 101 unique CNV call locations,
comprising 1197 individual CNV calls (1167 copy number gain
calls, 30 copy number loss calls), were not mapped to the new
build as the sequence they represented from build35 was either
partially deleted or split across more than region in build 36.
Statistical Analysis
The Pearson’s chi-squared test (1 degree of freedom) was used
for comparison of the number of ALS-specific and the number of
control-specific CNV loci. A two-tailed Fisher’s exact test was used
to test each autosomal CNV locus for differences between cases
and controls – losses and gains at a single locus were considered
together. A two-tailed Fisher’s exact test was also used for gene-
based association testing with losses and gains considered both
separately and together. Mann-Whitney U-tests were used for
comparison of CNV size and mean number per individual
between cases and controls. No multiple testing corrections were
applied. A significance threshold of P,0.05 was used.
Pathway Analysis
Gene Set analysis. Gene Set analysis (GSA) was undertaken
using the GenGen package [49] which implements the Gene-Set
Enrichment Analysis introduced by Subramanian, Tamayo et al
[50]. Significance was estimated empirically by permutation of the
phenotype labels (1000 permutations). All genes from Ensembl v54
(www.ensembl.org) that were overlapped by CNV regions defined
using a 70% reciprocal overlap threshold (plus 20 kb upstream
and downstream) were included in the analysis and the association
p-value from the overlapping CNV region was assigned to the
gene. We extended the coordinates by 20 kb as per Veyrieras et al.
(2008) who showed that approximately 95% of common SNPs
likely to affect gene expression reside in the proximal 20 kb to the
transcription start and end sites [51]. A total of 115 KEGG and
Gene Ontology level 4 gene sets containing between 20 and 200
genes were tested. Since many gene sets are redundant, the
effective number of pathways was calculated using an approach
previously proposed to calculate the effective number of tests for
genotype data [52]. A total of 87 effective pathways were tested
with a threshold of 5.74610
-4 defined by Bonferroni correction for
significance.
This analysis was also carried out using p-values from the gene-
based association testing. A total of 105 pathways that included 97
effective pathways was tested and a threshold for significance of
5.15610
24 was defined.
GRAIL. A GRAIL analysis [53] was carried out on ALS-
specific (n=119) and control-specific (n=136) CNV calls
Figure 3. Clustering CNV calls into CNV loci based on a
reciprocal overlap threshold of 50%. Each coloured bar represents
one CNV call in a single individual (note: the method used here cannot
distinguish overlapping calls in the same individual). CNV loci are
defined by vertical dashed lines. CNV locus 1 shows three CNV calls that
each share a greater than 50% reciprocal overlap with each of the other
CNV calls at that locus. Overlapping CNV loci 2 and 3 result from three
overlapping CNV calls, of which only two share a reciprocal overlap of
greater than 50%. CNV locus 4 and CNV locus 5 are an example of how
nested CNVs can occur.
doi:10.1371/journal.pone.0008175.g003
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same as the query region (in this case the CNV call coordinates)
due to the absence of any previously identified CNV regions
strongly associated with ALS. In brief, for each gene overlapped
by a query region all other human genes are given a relatedness
ranking using a similarity measure calculated by text mining of
PubMed abstracts. A count of all genes within all seed regions that
have a relatedness ranking less than a given threshold (which is
dependent on the number of genes within the seed region) for the
candidate gene is then obtained and a p value for the count
calculated. The best scoring gene within each query region is then
identified using the p value corrected for multiple testing according
to the number of candidate genes within the query region and any
genes that reach significance (p,0.05) are reported. The reported
genes are the genes with the most number of relationships to other
genes in independent associated regions.
Supporting Information
Appendix S1 Supplementary Methods: Simulations to define
filtering thresholds and alternative CNV call filtering strategy for
comparison with previous study.
Found at: doi:10.1371/journal.pone.0008175.s001 (0.03 MB
DOC)
Table S1 CNV regions showing significant association with ALS
but coordinates not transferable to build 36.
Found at: doi:10.1371/journal.pone.0008175.s002 (0.03 MB
DOC)
Table S2 Summary of all association results (p,0.05 using
Fishers exact test).
Found at: doi:10.1371/journal.pone.0008175.s003 (0.07 MB
DOC)
Table S3 Pathways nominally associated with ALS (P,0.05)
using GSA analysis. Both region-based and gene-based association
statistics were used.
Found at: doi:10.1371/journal.pone.0008175.s004 (0.04 MB
DOC)
Table S4 Result from GRAIL analysis of ALS-specific CNV
calls and control-specific CNV calls (corrected p,0.05).
Found at: doi:10.1371/journal.pone.0008175.s005 (0.03 MB
DOC)
Figure S1 Sensitivity and false positive rate for varying
thresholds of the log Bayes factor (simulation). Receiver Operating
Curve (ROC) curve showing sensitivity of CNV calls (1 -
proportion of false negative calls) and genome-wide number of
false positive calls for varying thresholds of the log Bayes factor.
Log Bayes factor thresholds up to .6 are indicated on the plot.
Found at: doi:10.1371/journal.pone.0008175.s006 (0.33 MB EPS)
Author Contributions
Conceived and designed the experiments: JEL CES PNL RHB AAC.
Analyzed the data: LVW IP MDT AAC. Contributed reagents/materials/
analysis tools: JEL GB CES PNL RHB AAC. Wrote the paper: LVW IP
MDT AAC. Conception and design of CNV association study: LVW
MDT. Conception and design of genome-wide association study: JEL CES
PNL RHB. Interpretation of findings: LVW IP JEL GB CES PNL RHB
MDT AAC. Critically revised the manuscript for important intellectual
content: JEL GB CES PNL RHB AAC.
References
1. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, et al. (2006)
Amyotrophic lateral sclerosis in an urban setting: a population based study of
inner city London. J Neurol 253: 1642–3.
2. Kabashi E, Valdmanis PN, Dion P, Rouleau GA (2007) Oxidized/misfolded
superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann
Neurol 62: 553–9.
3. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. (1993)
Mutations in Cu/Zn superoxide dismutase gene are associated with familial
amyotrophic lateral sclerosis. Nature 362: 59–62.
4. Siddique T, Figlewicz DA, Pericak-Vance MA, Haines JL, Rouleau G, et al.
(1991) Linkage of a gene causing familial amyotrophic lateral sclerosis to
chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 324:
1381–4.
5. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, et al. (2008) Novel
mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral
sclerosis. PLoS Genet 4: e1000193.
6. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, et al. (2008) TDP-43
mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319:
1668–72.
7. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, et al.
(2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial
amyotrophic lateral sclerosis. Science 323: 1205–8.
8. Hand CK, Devon RS, Gros-Louis F, Rochefort D, Khoris J, et al. (2003)
Mutation screening of the ALS2 gene in sporadic and familial amyotrophic
lateral sclerosis. Arch Neurol 60: 1768–71.
9. Hentati A, Bejaoui K, Pericak-Vance MA, Hentati F, Speer MC, et al. (1994)
Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-
q35. Nat Genet 7: 425–8.
10. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, et al. (2001) The gene
encoding alsin, a protein with three guanine-nucleotide exchange factor
domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat
Genet 29: 160–5.
11. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, et al. (2004) DNA/RNA
helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis
(ALS4). Am J Hum Genet 74: 1128–35.
12. Chen YZ, Hashemi SH, Anderson SK, Huang Y, Moreira MC, et al. (2006)
Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in
which recessive mutations cause ataxia and dominant mutations cause motor
neuron disease. Neurobiol Dis 23: 97–108.
13. McDermott CJ, Roberts D, Tomkins J, Bushby KM, Shaw PJ (2003) Spastin
and paraplegin gene analysis in selected cases of motor neurone disease (MND).
Amyotroph Lateral Scler Other Motor Neuron Disord 4: 96–9.
14. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, et al.
(2004) A mutation in the vesicle-trafficking protein VAPB causes late-onset
spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75:
822–31.
15. Al-Chalabi A, Andersen PM, Nilsson P, Chioza B, Andersson JL, et al. (1999)
Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis.
Hum Mol Genet 8: 157–64.
16. Figlewicz DA, Krizus A, Martinoli MG, Meininger V, Dib M, et al. (1994)
Variants of the heavy neurofilament subunit are associated with the development
of amyotrophic lateral sclerosis. Hum Mol Genet 3: 1757–61.
17. Tomkins J, Usher P, Slade JY, Ince PG, Curtis A, et al. (1998) Novel insertion in
the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis
(ALS). Neuroreport 9: 3967–70.
18. Crabtree B, Thiyagarajan N, Prior SH, Wilson P, Iyer S, et al. (2007)
Characterization of human angiogenin variants implicated in amyotrophic
lateral sclerosis. Biochemistry 46: 11810–8.
19. Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, et al. (2008)
Identification of new ANG gene mutations in a large cohort of Italian patients
with amyotrophic lateral sclerosis. Neurogenetics 9: 33–40.
20. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, et al. (2006) ANG
mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis.
Nat Genet 38: 411–3.
21. Hayward C, Colville S, Swingler RJ, Brock DJ (1999) Molecular genetic analysis
of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 52:
1899–901.
22. Wu D, Yu W, Kishikawa H, Folkerth RD, Iafrate AJ, et al. (2007) Angiogenin
loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol 62:
609–17.
23. van Es MA, Van Vught PW, Blauw HM, Franke L, Saris CG, et al. (2007)
ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a
genome-wide association study. Lancet Neurol 6: 869–77.
24. van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, et al. (2008)
Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral
sclerosis. Nat Genet 40: 29–31.
25. van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, et al. (2009)
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as
Copy Number Variation in ALS
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8175susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41:
1083–7.
26. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, et al. (2009)
Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene
increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad
Sci U S A 106: 9004–9.
27. Corcia P, Mayeux-Portas V, Khoris J, de Toffol B, Autret A, et al. (2002)
Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic
lateral sclerosis. Ann Neurol 51: 243–6.
28. Cronin S, Blauw HM, Veldink JH, van Es MA, Ophoff RA, et al. (2008)
Analysis of genome-wide copy number variation in Irish and Dutch ALS
populations. Hum Mol Genet 7: 7.
29. Blauw HM, Veldink JH, van Es MA, van Vught PW, Saris CG, et al. (2008)
Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide
screen. Lancet Neurol 28: 28.
30. Wang K, Li M, Hadley D, Liu R, Glessner J, et al. (2007) PennCNV: An
integrated hidden Markov model designed for high-resolution copy number
variation detection in whole-genome SNP genotyping data. Genome Res 5: 5.
31. Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, et al. (2006) High-
resolution genomic profiling of chromosomal aberrations using Infinium whole-
genome genotyping. Genome Res 16: 1136–48.
32. Colella S, Yau C, Taylor JM, Mirza G, Butler H, et al. (2007) QuantiSNP: an
Objective Bayes Hidden-Markov Model to detect and accurately map copy
number variation using SNP genotyping data. Nucleic Acids Res 35: 2013–25.
33. Wain LV, Armour JAL, Tobin MD (2009) Genomic copy number variation,
human health, and disease. Lancet 374: 340–50.
34. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, et al. (2008) Strong
association of de novo copy number mutations with sporadic schizophrenia. Nat
Genet 30: 30.
35. Potocki L, Bi W, Treadwell-Deering D, Carvalho CM, Eifert A, et al. (2007)
Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delin-
eation of a dosage-sensitive critical interval that can convey an autism
phenotype. Am J Hum Genet 80: 633–49.
36. Chen KS, Manian P, Koeuth T, Potocki L, Zhao Q, et al. (1997) Homologous
recombination of a flanking repeat gene cluster is a mechanism for a common
contiguous gene deletion syndrome. Nat Genet 17: 154–63.
37. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, et al. (2008)
Integrated detection and population-genetic analysis of SNPs and copy number
variation. Nat Genet 7: 7.
38. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, et al. (2008)
TARDBP mutations in individuals with sporadic and familial amyotrophic
lateral sclerosis. Nat Genet 40: 572–4.
39. Beleza-Meireles A, Al-Chalabi A (2009) Genetic studies of amyotrophic lateral
sclerosis: controversies and perspectives. Amyotroph Lateral Scler 10: 1–14.
40. Antonellis A, Lee-Lin SQ, Wasterlain A, Leo P, Quezado M, et al. (2006)
Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for
tRNA-charging enzymes in peripheral axons. J Neurosci 26: 10397–406.
41. Dubourg O, Azzedine H, Yaou RB, Pouget J, Barois A, et al. (2006) The G526R
glycyl-tRNA synthetase gene mutation in distal hereditary motor neuropathy
type V. Neurology 66: 1721–6.
42. Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, et al. (2006)
Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in
dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 38:
197–202.
43. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, et al. (2007) A
human phenome-interactome network of protein complexes implicated in
genetic disorders. Nat Biotechnol 25: 309–16.
44. Simpson CL, Lemmens R, Miskiewicz K, Broom WJ, Hansen VK, et al. (2009)
Variants of the elongator protein 3 (ELP3) gene are associated with motor
neuron degeneration. Hum Mol Genet 18: 472–81.
45. Jakobsson M, Scholz SW, Scheet P, Gibbs JR, VanLiere JM, et al. (2008)
Genotype, haplotype and copy-number variation in worldwide human
populations. Nature 451: 998–1003.
46. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al. (2004)
Detection of large-scale variation in the human genome. Nat Genet 36: 949–51.
47. Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, et al.
(1998) Mutations in the human lambda5/14.1 gene result in B cell deficiency
and agammaglobulinemia. J Exp Med 187: 71–7.
48. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, et al. (2008)
Deletion polymorphism upstream of IRGM associated with altered IRGM
expression and Crohn’s disease. Nat Genet 24: 24.
49. Wang K, Li M, Bucan M (2007) Pathway-based approaches for analysis of
genome-wide association studies. Am J Hum Genet 81: 1278–1283.
50. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–50.
51. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, et al. (2008)
High-resolution mapping of expression-QTLs yields insight into human gene
regulation. PLoS Genet 4: e1000214.
52. Gao X, Becker LC, Becker DM, Starmer JD, Province MA (2009) Avoiding the
high Bonferroni penalty in genome-wide association studies. Genet Epidemiol
11: 11.
53. Raychaudhuri S, Plenge RM, Rossin EJ, Ng ACY, Consortium IS, et al. (2009)
Identifying Relationships Among Genomic Disease Regions: Predicting Genes at
Pathogenic SNP Associations and Rare Deletions. PLoS Genet 5: e1000534.
Copy Number Variation in ALS
PLoS ONE | www.plosone.org 11 December 2009 | Volume 4 | Issue 12 | e8175